Instantly diagnose and manage respiratory disease using only a smartphone.
We provide point of care diagnostic solutions for telehealth that are easily integrated into existing platforms. We are working on apps to provide instant clinical quality diagnostic tests and management tools directly to consumers and healthcare providers.
ResAppDx is CE Marked in Europe and TGA approved in Australia.
A world-leading technology platform
Over the last five years the research team, led by Associate Professor Udantha Abeyratne at The University of Queensland, has pioneered algorithms that accurately characterise the state of patients’ respiratory tracts. The team has created a powerful platform for respiratory disease diagnosis and management which only requires the sound of the patient’s cough or breathing and does not require physical contact. With the high quality microphones in today’s smartphones the platform can be delivered without the need for additional hardware.
Latest Press Releases
October 22, 2020
October 21, 2020
September 28, 2020
September 21, 2020
September 1, 2020
August 4, 2020
Can an algorithm be trained to recognize different childhood coughs?
June 6, 2019
BMC On Health
Respiratory illnesses affect hundreds of millions of children worldwide. In this blog, Dr Paul Porter, author of a new study in Respiratory Research, talks about the development of a new tool for diagnosing childhood respiratory disease, using only a smartphone, acoustic analysis, and the power of mathematics. Read the article
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.